Investors tend to turn to big blue-chip dividend payers at times of market volatility, and in times past the steady earnings of pharma giants GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) have been a particular source of comfort when the market is falling. But in the recent lurch lower, London’s biggest drugs companies did just as badly as the FTSE 100. How come?
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.
Why Have GlaxoSmithKline plc And AstraZeneca plc Followed The FTSE 100 Down?
VIDEO: One Fool puts GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:AZN) under the spotlight.
You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.